🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

280 results for “LB” Clear

  1. Adebrelimab+Albumin paclitaxel +Cisplatin

    The First People's Hospital of Lianyungang

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  2. Albumin Paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Albuterol DPI 25 mcg/inh

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  4. Albuterol HFA-BOI

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule completed

    1 trial

  5. Apatinib

    The First People's Hospital of Lianyungang

    Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Atuliflapon, SALBUTAMOL, Placebo to Atuliflapon

    AstraZeneca AB

    Moderate-to-Severe Uncontrolled Asthma

    phase 2 small molecule active

    1 trial

  7. BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, GEMCITABINE, NIVOLUMAB, PEMETREXED, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  8. Belzutifan, PALBOCICLIB

    Merck Sharp and Dohme

    Advanced ccRCC

    phase 2 small molecule active

    1 trial

  9. Bleomycin medac, 15 000 RÜ süstelahuse pulber

    The George Institute

    VASCULAR MALFORMATION

    phase 2 small molecule active

    1 trial

  10. Bortezomib

    Takeda

    Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule completed

    1 trial

  11. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

    Daihong Liu

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

    phase 2 small molecule active

    1 trial

  12. CD19X CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-Cell Lymphoma (LBCL)

    phase 2 small molecule active

    1 trial

  13. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial

  14. CLBS12

    LISATA THERAPEUTICS, INC.

    Critical Limb Ischemia

    phase 2 mab completed

    1 trial

  15. CLBS14 (low-dose)

    LISATA THERAPEUTICS, INC.

    Myocardial Ischemia

    phase 2 mab completed

    1 trial

  16. CLBS16

    LISATA THERAPEUTICS, INC.

    Coronary Microvascular Dysfunction

    phase 2 mab terminated

    2 trials

  17. CORT125134, PACLITAXEL ALBUMIN-BOUND, BEVACIZUMAB, relacorilant

    CORCEPT THERAPEUTICS INC

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

  18. CPK850

    Novartis Pharmaceuticals

    Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene

    phase 2 small molecule active

    1 trial

  19. CYCLOPHOSPHAMIDE MONOHYDRATE, VINORELBINE, Tecentriq 840 mg concentrate for solution for infusion

    Istituto Gentili S.r.l.

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial

  20. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herst

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial

  23. Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasm

    phase 2 small molecule active

    1 trial

  24. Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

    United Therapeutics Europe Ltd

    Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources